300858.SZ
科拓生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.55
−5.52%Year over year
Reported trailing growth
- Revenue
- +16.2%
- EBITDA
- —
- EBIT
- -14.5%
- EPS
- -7.3%
- Free cash flow
- +26.4%
- Operating cash flow
- +16.2%
Forward estimates
Based on analyst estimates
- Revenue
- -77.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.3%
- EBITDA
- -1.4%
- EBIT
- -6.4%
- Net income
- -4.9%
- EPS
- -9.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026